Blackstone closed its inaugural royalty and structured credit-focused life sciences fund with $1.6 billion in investor commitments.
The Blackstone Life Sciences Yield fund was the largest first-time fund of this nature, according to officials at the $881 billion alternative investment firm. The strategy centers on post-approval, commercial-stage opportunities and complements Blackstone’s Life Sciences business, which invests in late-stage product development and is housed in Blackstone’s $261 billion private equity portfolio.
“Blackstone Life Sciences aim to invest across the full lifecycle of innovative medicines and medical technologies . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.